Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-world Study of Eribulin Mesylate-based Therapy in Patients With Advanced HER2-negative Breast Cancer Previously Treated With Antibody-drug Conjugates

NCT07480694 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT07480694
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07480694 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-world Study of Eribulin Mesylate-based Therapy in Patients With Advanced HER2-negative Breast Cancer Previously Treated With Antibody-drug Conjugates
Lead sponsor
Fudan University
Phase
Observational
Overall status
Not yet recruiting
Start date
March 31, 2026
Completion date
February 29, 2028
Enrollment
400 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

treatment efficacy